MedPath

Analysis the Positive Rate of Tumor Markers Among Physical Examination Population

Completed
Conditions
Tumor
Interventions
Other: no intervention
Registration Number
NCT05165147
Lead Sponsor
Peking University Third Hospital
Brief Summary

To analyze the positive rate of tumor markers (TM) among health examination population in a tertiary grade A class hospital, compare the differences between different age and sex groups, and explore the possible influencing factors of TM positive.

Detailed Description

From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study. The expression levels of carcinoembryonic antigen (CEA),α-fetoprotein (AFP), carbohydrate antigen 19-9 (CA 19-9), carbohydrate antigen-125 (CA-125), carbohydrate antigen 72-4(CA 72-4), carbohydrate antigen 15-3 (CA 15-3), carbohydrate antigen 242(CA 242), squamous cell carcinoma antigen(SCC), CYFRA21-1, total prostate-specific antigen (TPSA ) , free prostate-specific antigen(FPSA), neuron specific enolase(NSE) were detected by Electro chemistry luminescence method. The positive rates of TM were analyzed by descriptive statistical method Explore. The differences between different age and sex groups and the influencing factors were explored by statistic by Inferential statistical method.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
26891
Inclusion Criteria
  • Those who have taken a physical examination and performed at least one TM test
Read More
Exclusion Criteria
  • Basic information is missing and cannot be retrieved
  • The patient was diagnosed with malignant tumor before examination
  • Those who have not done any TM tests
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
physical examination populationno interventionFrom January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study.
Primary Outcome Measures
NameTimeMethod
the positive rate of neuron specific enolase( NSE)2019.01.01-2019.12.31

The proportion of abnormal NSE in physical examination population was calculated. The range of normal value :NSE≤17 ng/mL.

the positive rate of carbohydrate antigen 15-3(CA 15-3)2019.01.01-2019.12.31

The proportion of abnormal CA 15-3 in physical examination population was calculated. The range of normal value : CA 15-3≤25 IU/mL.

the positive rate of carbohydrate antigen 242(CA 242)2019.01.01-2019.12.31

The proportion of abnormal CA 242 in physical examination population was calculated. The range of normal value :CA 242≤20 U/mL.

the positive rate of squamous cell carcinoma antigen(SCC)2019.01.01-2019.12.31

The proportion of abnormal SCC in physical examination population was calculated. The range of normal value :SCC≤1.5 ng/mL.

the positive rate of carbohydrate antigen 19-9(CA 19-9)2019.01.01-2019.12.31

The proportion of abnormal CA 19-9 in physical examination population was calculated. The range of normal value : CA 19-9≤39 U/mL.

the positive rate of total prostate-specific antigen( TPSA)2019.01.01-2019.12.31

The proportion of abnormal TPSA in physical examination population was calculated. The range of normal value :TPSA≤4 ng/mL.

the positive rate of α-fetoprotein(AFP)2019.01.01-2019.12.31

The proportion of abnormal AFP in physical examination population was calculated. The range of normal value : AFP≤20 ng/mL.

the positive rate of carbohydrate antigen 72-4(CA 72-4)2019.01.01-2019.12.31

The proportion of abnormal CA 72-4 in physical examination population was calculated. The range of normal value : CA 72-4≤8.2 U/mL.

the positive rate of carcinoembryonic antigen(CEA)2019.01.01-2019.12.31

The proportion of abnormal CEA in physical examination population was calculated. The range of normal value : CEA≤5 ng/mL.

the positive rate of carbohydrate antigen 125(CA 125)2019.01.01-2019.12.31

The proportion of abnormal CA 125 in physical examination population was calculated. The range of normal value : CA 125≤35 U/mL.

the positive rate of Cytokeratin 19 fragment 21-1(CYFRA21-1)2019.01.01-2019.12.31

The proportion of abnormal CYFRA21-1 in physical examination population was calculated. The range of normal value :CYFRA21-1≤3.3 ng/mL.

the positive rate of free prostate-specific antigen( FPSA)2019.01.01-2019.12.31

The proportion of abnormal FPSA in physical examination population was calculated. The range of normal value :FPSA≤1 ng/mL.

Secondary Outcome Measures
NameTimeMethod
the measured value of Triglyceride (TG)2019.01.01-2019.12.31

TG measured on the day of physical examination.Unit of measure:mmol/L

the measured value of weight2019.01.01-2019.12.31

height measured on the day of physical examination.Unit of measure:kg

age2019.01.01-2019.12.31

the age of physical examination population.

the measured value of height2019.01.01-2019.12.31

height measured on the day of physical examination.Unit of measure:cm

the measured value of systolic blood pressure (SBP)2019.01.01-2019.12.31

SBP measured on the day of physical examination.Unit of measure:mmHg

the measured value of diastolic blood pressure (DBP)2019.01.01-2019.12.31

DBP measured on the day of physical examination.Unit of measure:mmHg

the measured value of fasting bood glucose (FBG)2019.01.01-2019.12.31

FBG measured on the day of physical examination.Unit of measure:mmol/L

the measured value of high density lipoprotein-cholesterol (HDL-C)2019.01.01-2019.12.31

HDL-C measured on the day of physical examination.Unit of measure:mmol/L

the measured value of total cholesterol (TC)2019.01.01-2019.12.31

TC measured on the day of physical examination.Unit of measure:mmol/L

the measured value of low density lipoprotein-cholesterol (LDL-C)2019.01.01-2019.12.31

LDL-C measured on the day of physical examination.Unit of measure:mmol/L

Body Mass Index (BMI)2019.01.01-2019.12.31

weight and height will be combined to report BMI in kg/m\^2

Trial Locations

Locations (1)

Peking University Third Hospital

🇨🇳

Beijing, China

© Copyright 2025. All Rights Reserved by MedPath